Immunome (NASDAQ:IMNM) Hits New 1-Year High on Analyst Upgrade

Immunome, Inc. (NASDAQ:IMNM)’s stock price reached a new 52-week high during trading on Tuesday after Stephens raised their price target on the stock from $25.00 to $33.00. Stephens currently has an overweight rating on the stock. Immunome traded as high as $18.79 and last traded at $18.13, with a volume of 1680551 shares trading hands. The stock had previously closed at $17.14.

Several other research analysts have also recently weighed in on IMNM. Evercore ISI assumed coverage on shares of Immunome in a report on Friday, August 22nd. They issued an “outperform” rating and a $18.00 price target on the stock. Craig Hallum began coverage on Immunome in a research note on Friday, September 5th. They set a “buy” rating and a $26.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $21.00 price target on shares of Immunome in a report on Friday, November 7th. Guggenheim reissued a “buy” rating and set a $25.00 target price on shares of Immunome in a report on Monday, August 25th. Finally, The Goldman Sachs Group initiated coverage on shares of Immunome in a research report on Monday, September 22nd. They issued a “buy” rating and a $26.00 target price for the company. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $23.78.

Institutional Investors Weigh In On Immunome

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMNM. Primecap Management Co. CA grew its holdings in shares of Immunome by 1,115.7% during the 1st quarter. Primecap Management Co. CA now owns 3,413,700 shares of the company’s stock valued at $22,974,000 after purchasing an additional 3,132,900 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Immunome by 37.4% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company’s stock worth $50,843,000 after acquiring an additional 2,054,640 shares during the period. Vanguard Group Inc. raised its position in shares of Immunome by 43.4% in the 1st quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company’s stock worth $28,987,000 after acquiring an additional 1,303,753 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Immunome by 222.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock valued at $12,939,000 after purchasing an additional 762,147 shares during the period. Finally, Woodline Partners LP boosted its position in shares of Immunome by 69.0% during the 1st quarter. Woodline Partners LP now owns 1,657,729 shares of the company’s stock valued at $11,157,000 after purchasing an additional 676,804 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors.

Immunome Stock Up 5.8%

The firm has a 50 day moving average of $13.72 and a 200 day moving average of $10.87. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of -6.15 and a beta of 1.96.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Equities analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.